Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?

Mélody Mazon1, Delphine Masi2, Madeleine Carreau3,4

  • 1CHU de Québec Research Center, 2705 Boulevard Laurier, RC-9800, Québec, QC G1V 4G2, Canada. melody.mazon@chudequebec.ulaval.ca.

Cancers
|July 2, 2016
PubMed

Insights

Dickkopf-1 (DKK1) protein is crucial in development and linked to bone diseases. This review explores DKK1

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Dickkopf-1 (DKK1) is a secreted antagonist of the Wnt/β-catenin pathway, essential for embryonic development.
  • Dysregulation of DKK1 is implicated in bone pathologies.
  • Emerging evidence links DKK1 to cancer progression and prognosis across various malignancies.

Purpose of the Study:

  • To provide a comprehensive overview of Dickkopf-1's role in cancer.
  • To explore the potential of DKK1 as a biomarker for cancer progression and prognosis.
  • To evaluate DKK1 as a therapeutic target for cancer treatment.

Main Methods:

  • Literature review of studies on Dickkopf-1.
  • Analysis of DKK1's involvement in Wnt/β-catenin signaling.
  • Examination of DKK1's association with different cancer types.

Main Results:

  • DKK1 plays a significant role in embryogenesis and cellular differentiation.
  • Elevated DKK1 levels are associated with adverse outcomes in several cancers.
  • Targeting DKK1 may offer a therapeutic strategy to inhibit cancer growth.

Conclusions:

  • Dickkopf-1 is a key regulator in development and disease.
  • DKK1 holds promise as a biomarker for cancer prognosis.
  • Inhibiting DKK1 presents a potential therapeutic avenue for cancer treatment.